子宮頸がんワクチンの世界市場レポート 2025年

子宮頸がんワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.0％で1,269億4,000万米ドルに成長します。予測期間の成長は、ワクチン接種範囲の拡大、定期予防接種プログラムへの統合、hpv検査とスクリーニングの進歩、hpvワクチン接種の世界の提唱、思春期のワクチン接種への注目の高まりなどに起因しています。予測期間における主な動向には、新しいアジュバントの導入、デジタルヘルスプラットフォームの統合、革新的なワクチン開発、官民パートナーシップ、教育キャンペーン、アドボカシーなどが含まれます。

子宮頸がんワクチン市場の成長軌道は、子宮頸がん患者の急増に後押しされて急上昇すると予測されます。子宮頸がんは、子宮頸部として知られる子宮下部を侵し、主にヒトパピローマウイルス（HPV）ワクチン接種の不徹底、不衛生な習慣、子宮頸がんに関する限られた認識や知識といった要因によって、報告症例の増加を目の当たりにしています。子宮頸がんワクチンは、高リスク型のヒトパピローマウイルス（HPV）を標的とすることで、この病気の予防に極めて重要な役割を果たしています。例えば、2023年1月、米国がん協会は米国だけで13,960例の子宮頸がんを報告しました。その結果、子宮頸がん罹患率の上昇が子宮頸がんワクチン市場成長の原動力となっています。

子宮頸がんワクチン市場の成長を大きく後押ししているのが、ヘルスケア支出の増加です。ヘルスケア支出とは、特定の地域や国のヘルスケア部門に割り当てられる総財源を指し、子宮頸がんワクチン接種の取り組みを支援する上で重要な役割を果たしています。子宮頸がんワクチンへの投資は、病気の発症を予防し、治療費に関連する経済的負担を軽減することを目的としています。さらに、この戦略的な資源配分は、大規模な医療介入の必要性を最小限に抑えることで、公衆衛生全体の成果を改善し、長期的な費用対効果を促進することを目的としています。例えば、2023年5月、英国の政府機関である国家統計局の報告によると、英国のヘルスケア支出は2022年から2023年にかけて5.6％増加し、2022年の0.9%増を大きく上回る見込みです。2023年には、英国のヘルスケア支出は約3,176億3,000万米ドル（2,920億英ポンド）に達します。したがって、ヘルスケア支出の増加は、子宮頸がんワクチン市場の拡大を促進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の子宮頸がんワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の子宮頸がんワクチン市場：成長率分析
• 世界の子宮頸がんワクチン市場の実績：規模と成長, 2019-2024
• 世界の子宮頸がんワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の子宮頸がんワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の子宮頸がんワクチン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• サーバリックス
• ガーダシル
• ガーダシル9
• 世界の子宮頸がんワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の子宮頸がんワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• バイオテクノロジー企業
• 学術研究機関
• その他のエンドユーザー
• 世界の子宮頸がんワクチン市場、サーバリックスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 投与スケジュール
• ターゲット層
• 世界の子宮頸がんワクチン市場、ガーダシルのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 投与スケジュール
• ターゲット層
• 世界の子宮頸がんワクチン市場、ガーダシル9のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 投与スケジュール
• ターゲット層

第7章 地域別・国別分析

• 世界の子宮頸がんワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の子宮頸がんワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 子宮頸がんワクチン市場：競合情勢
• 子宮頸がんワクチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Advaxis Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Immunovaccine Inc.
• AstraZeneca PLC
• EpiVax Inc.
• ImmunoVaccine Technologies Inc.
• OncoOne
• Xynomic Pharmaceuticals
• Vaxart Inc.
• Genentech Inc.
• Astellas Pharma Inc.
• MedImmune LLC
• Vaxine Pty Ltd
• Inovio Pharmaceuticals
• Advaxis Inc.
• ImmunoGen Inc.
• Gritstone Oncology, Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 子宮頸がんワクチン市場2029：新たな機会を提供する国
• 子宮頸がんワクチン市場2029：新たな機会を提供するセグメント
• 子宮頸がんワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The cervical cancer vaccine is designed to prevent cervical cancer by targeting high-risk types of human papillomavirus (HPV), the primary cause of most cervical cancer cases. These vaccines stimulate the body's immune response, generating antibodies to recognize and neutralize the HPV virus.

The main cervical cancer vaccines include Cervarix, Gardasil, and Gardasil 9. Cervarix is specifically formulated to protect against certain HPV strains associated with cervical cancer. These vaccines are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, reaching diverse end-users such as hospitals, biotechnology companies, academic and research organizations, among others.

The cervical cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides cervical cancer vaccine market statistics, including the cervical cancer vaccine industry global market size, regional shares, competitors with a cervical cancer vaccine market share, detailed cervical cancer vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the cervical cancer vaccine industry. This cervical cancer vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cervical cancer vaccine market size has grown strongly in recent years. It will grow from $87.36 billion in 2024 to $93.22 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to awareness campaigns and education, government initiatives and vaccination programs, increased incidence of cervical cancer, healthcare provider recommendations, global efforts for women's health

The cervical cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $126.94 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to expansion of vaccination coverage, integration into routine immunization programs, advancements in hpv testing and screening, global advocacy for hpv vaccination, rising focus on adolescent vaccination. Major trends in the forecast period include incorporation of new adjuvants, integration of digital health platforms, innovative vaccine development, public-private partnerships, educational campaigns and advocacy.

The growth trajectory of the cervical cancer vaccine market is anticipated to surge, propelled by the escalating prevalence of cervical cancer cases. Cervical cancer, affecting the lower part of the uterus known as the cervix, is witnessing an increase in reported cases, primarily attributed to factors such as inadequate Human papillomavirus (HPV) vaccination, poor hygiene practices, and limited awareness and knowledge concerning cervical cancer. Notably, cervical cancer vaccines play a pivotal role in preventing this disease by targeting high-risk types of human papillomavirus (HPV). For example, in January 2023, the American Cancer Society reported 13,960 cases of cervical cancer in the United States alone. Consequently, the rising incidence of cervical cancer cases serves as a driving force behind the growth of the cervical cancer vaccine market.

The increase in healthcare spending is significantly driving the growth of the cervical cancer vaccine market. Healthcare spending, which refers to the total financial resources allocated to the healthcare sector in a particular region or country, plays a vital role in supporting efforts for cervical cancer vaccination. Investment in cervical cancer vaccines aims to prevent the disease's onset and reduce the economic burden linked to treatment costs. Additionally, this strategic allocation of resources is designed to improve overall public health outcomes and promote long-term cost-effectiveness by minimizing the need for extensive medical interventions. For example, in May 2023, a report from the Office for National Statistics, a UK-based government department, noted that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth rate of 0.9% in 2022. In 2023, UK healthcare expenditure reached approximately $317.63 billion (£292 billion). Therefore, the rise in healthcare spending is a key factor driving the expansion of the cervical cancer vaccine market.

Product innovation stands out as a significant and growing trend within the cervical cancer vaccine market, with prominent market players directing their efforts towards the development of pioneering products to reinforce their market positions. An example of this trend occurred in May 2022 when GlaxoSmithKline, a UK-based pharmaceutical company, obtained approval from China's National Medical Products Administration (NMPA) for a two-dose schedule of its vaccine, Cervarix. This vaccine, intended for girls aged nine to fourteen, has been authorized to prevent cervical cancer. This approval marks a significant milestone as Cervarix becomes the first imported HPV vaccine to utilize a two-dose regimen for this specific age group in mainland China.

Major companies engaged in cervical cancer vaccines are strategically focusing on collaboration and partnerships to deliver reliable services to their clientele. These strategic partnerships involve structured alliances between multiple commercial enterprises, typically established through various business agreements or contracts. For instance, in June 2023, Nykode Therapeutics ASA, a Norway-based provider specializing in next-generation vaccines, expanded its collaboration with Roche Holding AG, a Switzerland-based healthcare company, to advance VB10.16, an off-the-shelf therapeutic cancer vaccine. The collaborative effort aims to evaluate VB10.16 in combination with Roche's atezolizumab (Tecentriq), an anti-PD-L1 immunotherapy, in patients diagnosed with advanced cervical cancer. This partnership holds promise in developing a novel and effective treatment option for a type of cancer that has limited treatment alternatives and typically poor prognoses.

In March 2024, Halma PLC, a UK-based technology company, acquired Rovers Medical Devices for €85 million. This acquisition is aimed at enhancing Halma PLC's offerings in the women's health sector, specifically in cervical cancer diagnostics. Rovers Medical Devices is a Netherlands-based manufacturing company that produces the only self-sampling device equipped with built-in features to ensure accurate sample collection and to provide reassurance to women.

Major companies operating in the cervical cancer vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co Inc., GlaxoSmithKline plc, Advaxis Inc., Immunovaccine Inc., AstraZeneca PLC, EpiVax Inc., ImmunoVaccine Technologies Inc., OncoOne, Xynomic Pharmaceuticals, Vaxart Inc., Genentech Inc., Astellas Pharma Inc., MedImmune LLC, Vaxine Pty Ltd, Inovio Pharmaceuticals, Advaxis Inc., ImmunoGen Inc., Gritstone Oncology, Inc., VBI Vaccines Inc., Genexine Inc., Aikido Pharma Inc., BioNTech SE, CureVac AG, Karyopharm Therapeutics, Epigenomics AG, Imugene Limited, Immunicum AB, Targovax ASA

North America was the largest region in the cervical cancer vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical cancer vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cervical cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cervical cancer vaccine market consists of sales of a gardiquimod, V503, silgard, and Human papillomavirus vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cervical Cancer Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cervical cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cervical cancer vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cervical cancer vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Cervarix; Gardasil; Gardasil 9
• 2) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End-Users: Hospital; Biotechnology Company; Academic And Research Organizations; Other End-Users
• Subsegments:
• 1) By Cervarix: Dosing Schedules; Target Demographics
• 2) By Gardasil: Dosing Schedules; Target Demographics
• 3) By Gardasil 9: Dosing Schedules; Target Demographics
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co Inc.; GlaxoSmithKline plc; Advaxis Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cervical Cancer Vaccine Market Characteristics

3. Cervical Cancer Vaccine Market Trends And Strategies

4. Cervical Cancer Vaccine Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Cervical Cancer Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cervical Cancer Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cervical Cancer Vaccine Market Growth Rate Analysis
• 5.4. Global Cervical Cancer Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cervical Cancer Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cervical Cancer Vaccine Total Addressable Market (TAM)

6. Cervical Cancer Vaccine Market Segmentation

• 6.1. Global Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cervarix
• Gardasil
• Gardasil 9
• 6.2. Global Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Biotechnology Company
• Academic and Research Organizations
• Other End-Users
• 6.4. Global Cervical Cancer Vaccine Market, Sub-Segmentation Of Cervarix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dosing Schedules
• Target Demographics
• 6.5. Global Cervical Cancer Vaccine Market, Sub-Segmentation Of Gardasil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dosing Schedules
• Target Demographics
• 6.6. Global Cervical Cancer Vaccine Market, Sub-Segmentation Of Gardasil 9, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dosing Schedules
• Target Demographics

7. Cervical Cancer Vaccine Market Regional And Country Analysis

• 7.1. Global Cervical Cancer Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cervical Cancer Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cervical Cancer Vaccine Market

• 8.1. Asia-Pacific Cervical Cancer Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cervical Cancer Vaccine Market

• 9.1. China Cervical Cancer Vaccine Market Overview
• 9.2. China Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cervical Cancer Vaccine Market

• 10.1. India Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cervical Cancer Vaccine Market

• 11.1. Japan Cervical Cancer Vaccine Market Overview
• 11.2. Japan Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cervical Cancer Vaccine Market

• 12.1. Australia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cervical Cancer Vaccine Market

• 13.1. Indonesia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cervical Cancer Vaccine Market

• 14.1. South Korea Cervical Cancer Vaccine Market Overview
• 14.2. South Korea Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cervical Cancer Vaccine Market

• 15.1. Western Europe Cervical Cancer Vaccine Market Overview
• 15.2. Western Europe Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cervical Cancer Vaccine Market

• 16.1. UK Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cervical Cancer Vaccine Market

• 17.1. Germany Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cervical Cancer Vaccine Market

• 18.1. France Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cervical Cancer Vaccine Market

• 19.1. Italy Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cervical Cancer Vaccine Market

• 20.1. Spain Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cervical Cancer Vaccine Market

• 21.1. Eastern Europe Cervical Cancer Vaccine Market Overview
• 21.2. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cervical Cancer Vaccine Market

• 22.1. Russia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cervical Cancer Vaccine Market

• 23.1. North America Cervical Cancer Vaccine Market Overview
• 23.2. North America Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cervical Cancer Vaccine Market

• 24.1. USA Cervical Cancer Vaccine Market Overview
• 24.2. USA Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cervical Cancer Vaccine Market

• 25.1. Canada Cervical Cancer Vaccine Market Overview
• 25.2. Canada Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cervical Cancer Vaccine Market

• 26.1. South America Cervical Cancer Vaccine Market Overview
• 26.2. South America Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cervical Cancer Vaccine Market

• 27.1. Brazil Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cervical Cancer Vaccine Market

• 28.1. Middle East Cervical Cancer Vaccine Market Overview
• 28.2. Middle East Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cervical Cancer Vaccine Market

• 29.1. Africa Cervical Cancer Vaccine Market Overview
• 29.2. Africa Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cervical Cancer Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Cervical Cancer Vaccine Market Competitive Landscape
• 30.2. Cervical Cancer Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Advaxis Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cervical Cancer Vaccine Market Other Major And Innovative Companies

• 31.1. Immunovaccine Inc.
• 31.2. AstraZeneca PLC
• 31.3. EpiVax Inc.
• 31.4. ImmunoVaccine Technologies Inc.
• 31.5. OncoOne
• 31.6. Xynomic Pharmaceuticals
• 31.7. Vaxart Inc.
• 31.8. Genentech Inc.
• 31.9. Astellas Pharma Inc.
• 31.10. MedImmune LLC
• 31.11. Vaxine Pty Ltd
• 31.12. Inovio Pharmaceuticals
• 31.13. Advaxis Inc.
• 31.14. ImmunoGen Inc.
• 31.15. Gritstone Oncology, Inc.

32. Global Cervical Cancer Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cervical Cancer Vaccine Market

34. Recent Developments In The Cervical Cancer Vaccine Market

35. Cervical Cancer Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Cervical Cancer Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cervical Cancer Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cervical Cancer Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer